ASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
The first-in-class EGFRxHER3 bispecific ADC that BMS paid $800 million for has shown strong phase 3 results from China that suggest it...
The first-in-class EGFRxHER3 bispecific ADC that BMS paid $800 million for has shown strong phase 3 results from China that suggest it...
In 2017, a little-known company called Nanjing Legend Biotech walked into the ASCO annual meeting at the 11th hour, dropped a 100%...
Days after its lead clinical-stage asset suffered a setback, Agios Pharmaceuticals has rebounded by buying a blood disorder drug that...
Within hours of securing a gastrointestinal drug from Korea’s Hanmi Pharma, Eli Lilly has ramped up the biobucks for a wider-ranging...
For biopharmaceutical companies, Japan is one of the world’s most important markets, but also among the most operationally complex. Many...
arXiv:2606.00555v2 Announce Type: replace-cross Abstract: Structure-based drug design increasingly employs LLM agents to iteratively...
Carbon-to-value biomanufacturing startup Intrinsic Foundries has raised Rs 12 crore to turn industrial carbon emissions into high-value...